Syngene International Limited (SYNGENE) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Syngene International Limited ₹346, price ₹361, upside -4.2%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.
How to read this chart
60‑month range ₹361.30 – ₹943.30 · fair‑value band ₹259.66 – ₹432.76 · the ₹361.30 price screens above the ₹346.20 fair value. Dashed = 300-day average. As of Oct 1, 2026.
Follow Syngene International in your weekly email
Every Wednesday you see whether Syngene International is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally.
Show more
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.
Stock analysis
Syngene International Limited (SYNGENE) currently trades at ₹361.30, while our model-based Fair Value estimate is ₹346.20, so the stock looks roughly fairly valued today (gap 4.4%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹255.80 per share, and 2 of the 26 models we run sit above the ₹361.30 price.
Bear case: the Asset-Based group reads lowest at ₹80.55, and 24 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹259.66 (bear) to ₹432.76 (bull), the price of ₹361.30 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Syngene International Limited reported revenue of ₹37.4B in FY2026 versus ₹26.0B in FY2022, a compound +9.5%/yr. Reported net income was ₹3.2B in FY2026, compounding −5.4%/yr from FY2022.
Key figures
Market cap ₹145B (≈ $1.5B) · P/E ratio 65.6 · P/S ratio 5.55 · EPS (TTM) ₹5.51 · Dividend yield 0.3% · Net margin 8.5% · Return on equity 6.6% · Return on assets (EBIT) 17.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 45% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −4%, SYNGENE screens cheaper than that median.
Fair Value models
Bear ₹259.66Fair Value ₹346.20Bull ₹432.76
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹2.17 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.84/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+2.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.3%
Start year 2021 (pandemic). Over 10 years: +12.9% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.0%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−4.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−4.9%
Dividend (yield on the price)0.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−4.9% vs 2.6%, slowing
Profit margin 2010 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 14%
Start year 2021 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+17.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+9.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +12.7% a year for the price and +5.4% for the forecasts.
Compare Syngene International Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 129 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score58 · Above median
Fair Value upside−4.2% · Above median
Profitability
Return on equity (TTM)6.6% · Above median
Return on assets4.8% · Above median
Net margin (TTM)6.1% · Above median
Operating margin (TTM)3.9% · Below median
Growth and dividend
Revenue growth−15.8% · Bottom 25%
Dividend yield (TTM)0.3% · Bottom 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Syngene International Limited Fair Value". https://www.fairvalue-calculator.com/stock/SYNGENE
Frequently asked questions
Is Syngene International Limited (SYNGENE) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of ₹346.20 versus a price of ₹361.30, about −4% upside (fairly valued).
What is the fair value of SYNGENE?
Our model-based fair value for Syngene International Limited is ₹346.20 (as of Oct 1, 2026), built from audited fundamentals. The current price: ₹361.30.
What is the quality score of SYNGENE?
Syngene International Limited has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Syngene International Limited (SYNGENE)?
Our model-based price target is the fair value of ₹346.20 (as of Oct 1, 2026) from 26 valuation models. Cautious scenario ₹259.66, optimistic scenario ₹432.76. It is a calculation from audited fundamentals, not an analyst target.
What is the Syngene International Limited stock forecast for 2026?
Our models put fair value at ₹346.20, about −4% upside versus a price of ₹361.30 (fairly valued). Cautious scenario ₹259.66, optimistic scenario ₹432.76. The calculation is refreshed regularly with new filings.
What is the revenue of Syngene International Limited (SYNGENE)?
Syngene International Limited reported trailing-twelve-month revenue of about ₹36.0B (latest available figure, as of Oct 1, 2026).
Does Syngene International Limited pay a dividend?
Syngene International Limited currently shows a dividend yield of about 0.35% relative to its recent price (as of Oct 1, 2026).
What growth is priced into Syngene International Limited (SYNGENE)?
For today's price to be fair in a discounted-cash-flow model, Syngene International Limited would have to grow free cash flow by +17.4 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.4 % per year. As of Oct 1, 2026.
What discount rate (WACC) does the fair value of SYNGENE use?
Our models discount Syngene International Limited at 12.4 %: a base by market capitalisation (small), damped by beta 0.08, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Syngene International Limited that is +17.4 % per year a year over ten years, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has Syngene International Limited (SYNGENE) delivered so far?
Over the past 5 years revenue at Syngene International Limited grew +11.4 % a year. The price currently implies +17.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Syngene International Limited (SYNGENE) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Syngene International Limited (+17.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Syngene International Limited (SYNGENE)?
The free-cash-flow yield on the price is 4.21 %: that much free cash flow Syngene International Limited produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Syngene International Limited (SYNGENE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Syngene International Limited it is ₹346.20 per share (as of Oct 1, 2026), against a price of ₹361.30. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Syngene International Limited stock overvalued or undervalued in 2026?
As of Oct 1, 2026, SYNGENE trades above its calculated fair value: price ₹361.30, fair value ₹346.20, a gap of about −4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SYNGENE?
No. The price is what the market pays today (₹361.30); the fair value is what the company's own numbers justify (₹346.20). For Syngene International Limited the two are ₹15.10 per share apart. That gap is exactly why we show both numbers side by side.
How much is Syngene International Limited worth?
The market values Syngene International Limited at about ₹145B (market capitalisation, as of Oct 1, 2026). Per share that is ₹361.30; our models calculate a fair value of ₹346.20 per share.
What do the bullish and bearish scenarios say about SYNGENE?
Our models span a range for Syngene International Limited: cautious scenario ₹259.66, base ₹346.20, optimistic ₹432.76 per share (as of Oct 1, 2026, price ₹361.30). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SYNGENE?
Syngene International Limited trades at a price-to-earnings ratio of 65.6 (as of Oct 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹346.20 is built from several models across several years. Excluding one-off items of fiscal year 2026 it is 38.7 (reported for FY2026: 45.9). Other multiples: P/B 3.0, P/S 4.0, EV/EBITDA 15.9.
How solid is the balance sheet of Syngene International Limited (SYNGENE)?
Balance-sheet figures for Syngene International Limited (as of Oct 1, 2026): return on equity 6.6%. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is SYNGENE from its 52-week high?
Syngene International Limited trades at ₹361.30, about 45% below its 52-week high of ₹661.98 and at the low of ₹361.30 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹346.20 is for.
Which stocks are comparable to Syngene International Limited?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Syngene International Limited stock attractive at the current price?
The data as of Oct 1, 2026: price ₹361.30, calculated fair value ₹346.20 (−4%), Quality Score 58/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SYNGENE calculated?
We run Syngene International Limited through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹346.20, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1 % above its aggregate fair value. Syngene International Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Syngene International Limited (SYNGENE)?
The closing price on Oct 1, 2026 was ₹361.30. Our model-based fair value is ₹346.20, about −4% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Syngene International Limited right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the upper half of our model range, so the margin of safety is thin. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Syngene International Limited (SYNGENE) come from?
Earnings per share at Syngene International Limited grew +7.0 % a year from 2015 to 2026. Broken into its drivers: revenue per share +14.4 %, EBIT margin −3.8 %, tax rate −0.9 %, residual (interest, one-offs) −2.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Syngene International Limited
How large is the market capitalisation of Syngene International Limited (SYNGENE)?
The market capitalisation of Syngene International Limited is ₹145B (≈ $1.5B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Syngene International Limited (SYNGENE)?
The price-to-sales ratio of Syngene International Limited is 5.55 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Syngene International Limited (SYNGENE)?
Earnings per share at Syngene International Limited are ₹5.51 (price ÷ EPS = P/E 65.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Syngene International Limited (SYNGENE)?
The dividend yield of Syngene International Limited is 0.3% (payout 19.1%, on adjusted earnings, reported 22.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Syngene International Limited (SYNGENE)?
The net margin of Syngene International Limited is 8.5% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Syngene International Limited (SYNGENE)?
The return on equity (ROE) of Syngene International Limited is 6.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Syngene International Limited (SYNGENE)?
On an EBIT basis the return on assets of Syngene International Limited is 17.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Syngene International Limited (SYNGENE)?
The operating margin of Syngene International Limited is 3.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Syngene International Limited (SYNGENE)?
Revenue at Syngene International Limited is growing −15.8% versus a year earlier (3y avg +5.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Syngene International Limited (SYNGENE)?
Earnings per share at Syngene International Limited are growing −19.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Syngene International Limited (SYNGENE) hold?
Syngene International Limited holds more cash than debt, ₹3.7B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
